Skip to main content
SpringerLink
Log in

Pharmacogenetics of Membrane Transporters

A Review of Current Approaches

  • Protocol
Pharmacogenomics in Drug Discovery and Development

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 448))

Summary

This chapter provides a review of the pharmacogenetics of mem brane transporters, including adenosine triphosphate-binding cassette (ABC) transporters and organic anion transporting proteins (OATPs). Membrane trans porters are heavily involved in drug disposition by actively transporting substrate drugs between organs and tissues. As such, polymorphisms in the genes encoding these proteins may have a significant effect on the absorption, distribution, metabo lism, and excretion of compounds. The techniques used to identify substrates and inhibitors of these proteins and subsequently assess the effect of genetic mutation on transport, both in vitro and in vivo, are outlined and discussed. Finally, studies linking transporter genotype with clinical outcomes are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295–1302.

    Article  CAS  PubMed  Google Scholar 

  2. Dean, M., Rzhetsky, A., and Allikmets, R. (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156–1166.

    Article  CAS  PubMed  Google Scholar 

  3. Gottesman, M. M., and Ambudkar, S. V. (2001) Overview: ABC transporters and human dis ease. J. Bioenerg. Biomembr. 33, 453–458.

    Article  CAS  PubMed  Google Scholar 

  4. Lepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D., and Sparreboom, A. (2005) Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC trans porters ABCB1 and ABCG2. Pharmacogenomics. 6, 115–138.

    Article  CAS  PubMed  Google Scholar 

  5. Fojo, A. T., Shen, D. W., Mickley, L. A., Pastan, I., and Gottesman, M. M. (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J. Clin. Oncol. 5, 1922–1927.

    CAS  PubMed  Google Scholar 

  6. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., et al. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458–3464.

    CAS  PubMed  Google Scholar 

  7. Schellens, J. H., Malingre, M. M., Kruijtzer, C. M., et al. H. (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur. J. Pharm. Sci. 12, 103–110.

    Article  CAS  PubMed  Google Scholar 

  8. Schinkel, A. H., Mayer, U., Wagenaar, E., et al. (1997) Normal viability and altered pharma-cokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 94, 4028–4033.

    Article  CAS  PubMed  Google Scholar 

  9. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84, 7735–7738.

    Article  CAS  PubMed  Google Scholar 

  10. Gottesman, M. M., and Ambudkar, S. V. (2001) Overview: ABC transporters and human dis ease. J. Bioenerg. Biomembr. 33, 453–458.

    Article  CAS  PubMed  Google Scholar 

  11. Xiao, J. J., Foraker, A. B., Swaan, P. W., et al. (2005) Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 313, 268–276.

    Article  CAS  PubMed  Google Scholar 

  12. Chaudhary, P. M., and Roninson, I. B. (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85–94.

    Article  CAS  PubMed  Google Scholar 

  13. Eichelbaum, M., Fromm, M. F., and Schwab, M. (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180–185.

    Article  CAS  PubMed  Google Scholar 

  14. Fromm, M. F. (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423–429.

    Article  CAS  PubMed  Google Scholar 

  15. Meissner, K., Sperker, B., Karsten, C., et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem. 50, 1351–1356.

    CAS  PubMed  Google Scholar 

  16. Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., et al. (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood cerebrospinal-fluid drug–permeability barrier. Proc. Natl. Acad. Sci. U. S. A. 96, 3900–3905.

    Article  CAS  PubMed  Google Scholar 

  17. Saito, T., Zhang, Z. J., Ohtsubo, T., et al. (2001) Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol. 121, 735–742.

    Article  CAS  PubMed  Google Scholar 

  18. Wijnholds, J., deLange, E. C., Scheffer, G. L., et al. (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood–cerebrospinal fluid bar rier. J. Clin. Invest. 105, 279–285.

    Article  CAS  PubMed  Google Scholar 

  19. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (1999) The multidrug resistance protein fam ily. Biochim. Biophys. Acta. 1461, 347–357.

    Article  CAS  PubMed  Google Scholar 

  20. Cascorbi, I. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457–473.

    Article  CAS  PubMed  Google Scholar 

  21. Deeley, R. G., and Cole, S. P. (2006) Substrate recognition and transport by multidrug resis tance protein 1 (ABCC1). FEBS Lett. 580, 1103–1111.

    Article  CAS  PubMed  Google Scholar 

  22. Ho, R. H., and Kim, R. B. (2005) Transporters and drug therapy: implications for drug disposi tion and disease. Clin. Pharmacol. Ther. 78, 260–277.

    Article  CAS  PubMed  Google Scholar 

  23. Smith, N. F., Figg, W. D., and Sparreboom, A. (2005) Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol. 1, 429–445.

    Article  CAS  PubMed  Google Scholar 

  24. Kurata, Y., Ieiri, I., Kimura, M., et al. (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72, 209–219.

    Article  CAS  PubMed  Google Scholar 

  25. Meissner, K., Sperker, B., Karsten, C., et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem. 50, 1351–1356.

    CAS  PubMed  Google Scholar 

  26. Tanabe, M., Ieiri, I., Nagata, N., et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297, 1137–1143.

    CAS  PubMed  Google Scholar 

  27. Yi, S. Y., Hong, K. S., Lim, H. S., et al. (2004) A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76, 418–427.

    Article  CAS  PubMed  Google Scholar 

  28. Sun, J., He, Z. G., Cheng, G., Wang, S. J., Hao, X. H., and Zou, M. J. (2004) Multidrug resist ance P-glycoprotein: crucial significance in drug disposition and interaction. Med. Sci. Monit. 10, RA5–RA14.

    CAS  PubMed  Google Scholar 

  29. Imai, Y., Nakane, M., Kage, K., et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611–616.

    CAS  PubMed  Google Scholar 

  30. Kobayashi, D., Ieiri, I., Hirota, T., et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33, 94–101.

    Article  CAS  PubMed  Google Scholar 

  31. Kolwankar, D., Glover, D. D., Ware, J. A., and Tracy, T. S. (2005) Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab. Dispos. 33, 524–529.

    Article  CAS  PubMed  Google Scholar 

  32. Kondo, C., Suzuki, H., Itoda, M., et al. (2004) Functional analysis of SNPs variants of BCRP/ ABCG2. Pharm. Res. 21, 1895–1903.

    Article  CAS  PubMed  Google Scholar 

  33. Sparreboom, A., Gelderblom, H., Marsh, S., et al. (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 76, 38–44.

    Article  CAS  PubMed  Google Scholar 

  34. Mizuarai, S., Aozasa, N., and Kotani, H. (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 109, 238–246.

    Article  CAS  PubMed  Google Scholar 

  35. de Jong, F. A., Marsh, S., Mathijssen, R. H., et al. (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10, 5889–5894.

    Article  PubMed  Google Scholar 

  36. Imai, Y., Nakane, M., Kage, K., et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611–616.

    CAS  PubMed  Google Scholar 

  37. Kondo, C., Suzuki, H., Itoda, M., et al. (2004) Functional analysis of SNPs variants of BCRP/ ABCG2. Pharm. Res. 21, 1895–1903.

    Article  CAS  PubMed  Google Scholar 

  38. Allen, J. D., Jackson, S. C., and Schinkel, A. H. (2002) A mutation hot spot in the BCRPl (ABCG2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res. 62, 2294–2299.

    CAS  PubMed  Google Scholar 

  39. Honjo, Y., Hrycyna, C. A., Yan, Q. W., et al. (2001) Acquired mutations in the MXR/BCRP/ ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61, 6635–6639.

    CAS  PubMed  Google Scholar 

  40. Robey, R. W., Honjo, Y., Morisaki, K., et al. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971–1978.

    Article  CAS  PubMed  Google Scholar 

  41. Robey, R. W., Steadman, K., Polgar, O., et al. (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64, 1242–1246.

    Article  CAS  PubMed  Google Scholar 

  42. Letourneau, I. J., Deeley, R. G., and Cole, S. P. (2005) Functional characterization of non synonymous single nucleotide polymorphisms in the gene encoding human multidrug resist ance protein 1 (MRP1/ABCC1). Pharmacogenet. Genomics. 15, 647–657.

    Article  CAS  PubMed  Google Scholar 

  43. Oselin, K., Mrozikiewicz, P. M., Gaikovitch, E., Pahkla, R., and Roots, I. (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detec tion of a novel mutation G816A in the human MRP1 gene. Eur. J. Clin. Pharmacol. 59, 347–350.

    Article  CAS  PubMed  Google Scholar 

  44. Tirona, R. G., Leake, B. F., Merino, G., and Kim, R. B. (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669–35675.

    Article  CAS  PubMed  Google Scholar 

  45. Nozawa, T., Nakajima, M., Tamai, I., et al. (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804–813.

    Article  CAS  PubMed  Google Scholar 

  46. Colburn, W. A. (2003) Biomarkers in drug discovery and development: from target identifica tion through drug marketing. J. Clin. Pharmacol. 43, 329–341.

    Article  PubMed  Google Scholar 

  47. Cole, S. P., Bhardwaj, G., Gerlach, J. H., et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258, 1650–1654.

    Article  CAS  PubMed  Google Scholar 

  48. Hesselink, D. A., van Schaik, R. H., van der Heiden, I. P., et al. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibi tors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245–254.

    Article  CAS  PubMed  Google Scholar 

  49. Noe, B., Hagenbuch, B., Stieger, B., and Meier, P. J. (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U. S. A. 94, 10346–10350.

    Article  CAS  PubMed  Google Scholar 

  50. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., and Kim, R. B. (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866–871.

    CAS  PubMed  Google Scholar 

  51. Aszalos, A. (2004) P-glycoprotein-based drug-drug interactions: preclinical methods and rel evance to clinical observations. Arch. Pharm. Res. 27, 127–135.

    Article  CAS  PubMed  Google Scholar 

  52. Smith, N. F., Acharya, M. R., Desai, N., Figg, W. D., and Sparreboom, A. (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4, 815–818.

    Article  CAS  PubMed  Google Scholar 

  53. Hitzl, M., Drescher, S., van der Kuip, H., et al. (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56† natural killer cells. Pharmacogenetics. 11, 293–298.

    Article  CAS  PubMed  Google Scholar 

  54. Schaefer, M., Roots, I., and Gerloff, T. (2005) In vitro transport characteristics discriminate wildtype mdr1 (abcb1) from ala893ser and ala893thr polymorphisms. Eur. J. Clin. Pharmacol. 61, 718.

    Google Scholar 

  55. Ishikawa, T., Sakurai, A., Kanamori, Y., et al. (2005) High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharma-cogenomics. Methods Enzymol. 400, 485–510.

    Article  CAS  PubMed  Google Scholar 

  56. Morisaki, K., Robey, R. W., Ozvegy-Laczka, C., et al. (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56, 161–172.

    Article  CAS  PubMed  Google Scholar 

  57. Robey, R. W., Honjo, Y., Morisaki, K., et al. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer. 89, 1971–1978.

    Article  CAS  PubMed  Google Scholar 

  58. Zhang, Y., Gupta, A., Wang, H., et al. (2005) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22, 2023–2034.

    Article  CAS  PubMed  Google Scholar 

  59. Nakamura, Y., Oka, M., Soda, H., et al. (2005) Gefitinib (“Iressa,” ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ ABCG2-mediated drug resistance. Cancer Res. 65, 1541–1546.

    Article  CAS  PubMed  Google Scholar 

  60. Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., and Sugiyama, Y. (2004) Functional analysis of sin gle nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics. 14, 749–757.

    Article  CAS  PubMed  Google Scholar 

  61. Michalski, C., Cui, Y., Nies, A. T., et al. (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277, 43058–43063.

    Article  CAS  PubMed  Google Scholar 

  62. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., and Tamai, I. (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymor phisms. Drug Metab. Dispos. 33, 434–439.

    Article  CAS  PubMed  Google Scholar 

  63. Tirona, R. G., Leake, B. F., Wolkoff, A. W., and Kim, R. B. (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223–228.

    Article  CAS  PubMed  Google Scholar 

  64. Hoffmeyer, S., Burk, O., von Richter, O., et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97, 3473–3478.

    Article  CAS  PubMed  Google Scholar 

  65. Song, P., Lamba, J. K., Zhang, L., et al. (2006) G2677T and C3435T genotype and haplo type are associated with hepatic ABCB1 (MDR1) expression. J. Clin. Pharmacol. 46, 373–379.

    Article  CAS  PubMed  Google Scholar 

  66. Meissner, K., Jedlitschky, G., Meyer zu Schwabedissen, H., et al. (2004) Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary poly morphisms. Pharmacogenetics. 14, 381–385.

    Article  CAS  PubMed  Google Scholar 

  67. Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L., and Sadee, W. (2005) Multidrug resist ance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics. 15, 693–704.

    Article  CAS  PubMed  Google Scholar 

  68. Zamber, C. P., Lamba, J. K., Yasuda, K., et al. (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 13, 19–28.

    Article  CAS  PubMed  Google Scholar 

  69. Kimchi-Sarfaty, C., Gribar, J. J., and Gottesman, M. M. (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1–6.

    Article  CAS  PubMed  Google Scholar 

  70. Lin, J. H., and Yamazaki, M. (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59–98.

    Article  CAS  PubMed  Google Scholar 

  71. Schinkel, A. H., Smit, J. J., van Tellingen, O., et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77, 491–502.

    Article  CAS  PubMed  Google Scholar 

  72. Sparreboom, A., van Asperen, J., Mayer, U., et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 94, 2031–2035.

    Article  CAS  PubMed  Google Scholar 

  73. Smit, J. W., Huisman, M. T., van Tellingen, O., Wiltshire, H. R., and Schinkel, A. H. (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104, 1441–1447.

    Article  CAS  PubMed  Google Scholar 

  74. Allen, J. D., Brinkhuis, R. F., van Deemter, L., Wijnholds, J., and Schinkel, A. H. (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 60, 5761–5766.

    CAS  PubMed  Google Scholar 

  75. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. (1999) The mouse Bcrp1/ Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topo tecan, mitoxantrone, or doxorubicin. Cancer Res. 59, 4237–4241.

    CAS  PubMed  Google Scholar 

  76. Gallo, J. M., Li, S., Guo, P., Reed, K., and Ma, J. (2003) The effect of P-glycoprotein on pacli taxel brain and brain tumor distribution in mice. Cancer Res. 63, 5114–5117.

    CAS  PubMed  Google Scholar 

  77. Ejsing, T. B., Pedersen, A. D., and Linnet, K. (2005) P-glycoprotein interaction with risperi done and 9-OH-risperidone studied in vitro, in knock-out mice and in drug–drug interaction experiments. Hum. Psychopharmacol. 20, 493–500.

    Article  CAS  PubMed  Google Scholar 

  78. Doran, A., Obach, R. S., Smith, B. J., et al. (2005) The impact of P-glycoprotein on the dispo sition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33, 165–174.

    Article  CAS  PubMed  Google Scholar 

  79. Johne, A., Kopke, K., Gerloff, T., et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584–594.

    Article  CAS  PubMed  Google Scholar 

  80. Verstuyft, C., Schwab, M., Schaeffeler, E., et al. (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 58, 809–812.

    CAS  PubMed  Google Scholar 

  81. Sakaeda, T. (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet. 20, 391–414.

    Article  CAS  PubMed  Google Scholar 

  82. Lin, S. K., Su, S. F., and Pan, C. H. (2006) Higher plasma drug concentration in clozapinetreated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther. Drug Monit. 28, 303–307.

    Article  CAS  PubMed  Google Scholar 

  83. Sissung, T. M., Mross, K., Steinberg, S. M., et al. (2006) Association of ABCB1 geno types with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer. 42, 2893–2896.

    Article  CAS  PubMed  Google Scholar 

  84. Niemi, M., Schaeffeler, E., Lang, T., et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 14, 429–440.

    Article  CAS  PubMed  Google Scholar 

  85. Niemi, M., Neuvonen, P. J., Hofmann, U., et al. (2005) Acute effects of pravastatin on choles terol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics. 15, 303–309.

    Article  CAS  PubMed  Google Scholar 

  86. Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., et al. (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375–380.

    Article  CAS  PubMed  Google Scholar 

  87. Schaefer, M., Roots, I., and Gerloff, T. (2006) In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet. Genomics. 16, 855–861.

    Article  CAS  PubMed  Google Scholar 

  88. Kim, R. B., Leake, B. F., Choo, E. F., et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189–199.

    Article  CAS  PubMed  Google Scholar 

  89. Goh, B. C., Lee, S. C., Wang, L. Z., et al. (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and geno typing strategies. J. Clin. Oncol. 20, 3683–3690.

    Article  CAS  PubMed  Google Scholar 

  90. Isla, D., Sarries, C., Rosell, R., et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194–1203.

    Article  CAS  PubMed  Google Scholar 

  91. Puisset, F., Chatelut, E., Dalenc, F., et al. (2004) Dexamethasone as a probe for docetaxel clear ance. Cancer Chemother. Pharmacol. 54, 265–272.

    Article  CAS  PubMed  Google Scholar 

  92. Wils, P., Phung-Ba, V., Warnery, A., et al. (1994) Polarized transport of docetaxel and vinblas tine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48, 1528–1530.

    Article  CAS  PubMed  Google Scholar 

  93. Sparreboom, A., Loos, W. J., Burger, H., et al. (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. 4, 650–658.

    CAS  PubMed  Google Scholar 

  94. Gardner, E. R., Burger, H., van Schaik, R. H., et al. (2006) Association of enzyme and trans porter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 80, 192–201.

    Article  CAS  PubMed  Google Scholar 

  95. Mwinyi, J., Johne, A., Bauer, S., Roots, I., and Gerloff, T. (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415–421.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

    Tristan M. Sissung, Rui Gao & William D. Figg

  2. Clinical Pharmacology Program, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland

    Erin R. Gardner

Authors
  1. Tristan M. Sissung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin R. Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William D. Figg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. PharmTao, Santa Clara, CA, USA

    Qing Yan

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Sissung, T.M., Gardner, E.R., Gao, R., Figg, W.D. (2008). Pharmacogenetics of Membrane Transporters. In: Yan, Q. (eds) Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology™, vol 448. Humana Press. https://doi.org/10.1007/978-1-59745-205-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-205-2_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-887-4

  • Online ISBN: 978-1-59745-205-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation